Publications

Listed below is a selection of recent publications from the Vaughan Lab. See a full list on PubMed.

A Plasmodium parasite with complete late liver stage arrest protects against preerythrocytic and erythrocytic stage infection in mice. Vaughan AM, Sack BK, Dankwa D, Minkah N, Nguyen T, Cardamone H, Kappe SH. Infect Immun. 2018;86(5).

Plasmodium falciparum genetic crosses in a humanized mouse model. Vaughan AM, Pinapati RS, Cheeseman IH, Camargo N, …Kappe SH. Nature Methods. 2015 Jul;12(7):631-3.

Plasmodium vivax liver stage development and hypnozoite persistence in human liver-chimeric mice. Vaughan AM, Mikolajczak SA, Kangwanrangsan N, Roobsoong W, Fishbaugher M, Yimamnuaychok N, Rezakhani N, Lakshmanan V, Singh N, Kaushansky A, Camargo N, Baldwin M, Lindner SE, Adams JH, Sattabongkot J, Kappe SH. Cell Host Microbe. 2015;17(4):526-35.

A Plasmodium yoelii Mei2-Like RNA binding protein is essential for completion of liver stage schizogony. Dankwa DA, Davis MJ, Kappe SH, Vaughan AM. Infect Immun. 2016;84(5):1336-45.

Enzymes involved in plastid-targeted phosphatidic acid synthesis are essential for Plasmodium yoelii liver-stage development. Lindner SE, Sartain MJ, Hayes K, Harupa A, Moritz RL, Kappe SH, Vaughan AM. Mol Microbiol. 2014;91(4):679-93.

Complete Plasmodium falciparum liver-stage development in liver-chimeric mice. Vaughan AM, Mikolajczak SA, Wilson EM, Grompe M, Kaushansky A, Camargo N, Bial J, Ploss A, Kappe SH. J Clin Invest. 2012;122(10):3618-28. Epub 2012/09/22.

Type II fatty acid synthesis is essential only for malaria parasite late liver stage development. Vaughan AM, O’Neill MT, Tarun AS, Camargo N, Phuong TM, Aly AS, Cowman AF, Kappe SH. Cell Microbiol. 2009;11(3):506-20.

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.